What NAD+ Actually Is — and Why It Declines
Nicotinamide adenine dinucleotide — NAD+ — is a coenzyme found in every living cell. It sits at the center of hundreds of biological processes: converting food into energy via the mitochondrial electron transport chain, activating sirtuins (proteins involved in DNA repair and gene expression), and fueling enzymes called PARPs that patch damaged DNA. In short, NAD+ is not a fringe molecule. It is fundamental to how cells function and maintain themselves.
The problem is that NAD+ levels fall substantially as we age. Studies using mass spectrometry to measure tissue NAD+ concentrations in humans and animal models have found reductions of 40–60% between young adulthood and midlife in muscle, liver, and brain tissue. A 2020 analysis published in Cell Metabolism confirmed this decline in skeletal muscle biopsies from older adults, linking lower NAD+ to reduced mitochondrial function and physical capacity.
This decline has a plausible mechanism. As we age, an enzyme called CD38 becomes more active and consumes NAD+ at a higher rate. Simultaneously, chronic low-grade inflammation — sometimes called “inflammaging” — increases PARP activity, further depleting the pool. The body can synthesize NAD+ from the amino acid tryptophan and from B-vitamin precursors in the diet, but the rate of synthesis appears insufficient to keep pace with accelerating consumption in older adults.
This is where NAD+ supplements enter the picture. Rather than supplying NAD+ directly (it is poorly absorbed intact), supplements deliver biochemical precursors that the body converts into NAD+. The two most studied are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). how mitochondria decline with age
What the Research Says
The NAD+ field has moved from almost entirely animal studies five years ago to a growing body of human trials. That is progress — but it is important to read those trials carefully before drawing conclusions.
NAD+ Precursors Do Raise Blood NAD+ Levels in Humans
The most consistent finding across human trials is that both NR and NMN reliably increase NAD+ concentrations in blood. A 2018 randomized controlled trial (RCT) published in Nature Communications by Martens et al. found that supplementing with 1,000 mg/day of NR for six weeks raised whole blood NAD+ by approximately 60% in healthy middle-aged and older adults compared with placebo. A 2021 RCT in npj Aging and Mechanisms of Disease found similar results with NMN at 250 mg/day over 12 weeks in older men.
However, there is an important caveat: blood NAD+ levels are a biomarker, not a clinical outcome. Raising blood NAD+ is a bit like raising a car’s engine temperature to its optimal range — it is a necessary condition for performance, but not proof that performance has improved. Whether blood increases reflect meaningful changes in brain, heart, or muscle tissue NAD+ in living humans is still not established.
Muscle Function and Exercise Capacity
Animal data showing that NAD+ precursors improve muscle function, endurance, and even reverse some aspects of age-related muscle decline generated enormous excitement. Human translation has been more modest. A 2020 RCT published in Cell Reports Medicine by Dolopikou et al. found that NR supplementation (1,000 mg/day for 21 days) improved mitochondrial function markers and reduced oxidative stress in older adults, though exercise performance was not measured as an endpoint. A separate 2023 trial in Journal of Physiology found no significant benefit of NMN supplementation on aerobic capacity in recreationally active older adults over 12 weeks, adding a note of caution to overly optimistic extrapolations from mouse studies.
Cardiometabolic Markers
Several small trials have examined blood pressure, blood lipids, and insulin sensitivity. A 2018 pilot study in Nature Communications found no significant change in blood pressure, body composition, or lipid profiles after six weeks of NR in older adults, though the sample size (n=24) limited statistical power. More promising results came from a 2022 study in Frontiers in Aging, which found that NMN at 250–500 mg/day for 12 weeks improved insulin sensitivity and reduced triglycerides in overweight middle-aged adults — though this trial was funded by an NMN manufacturer, warranting cautious interpretation.
Cognitive Function and Brain Health
NAD+ aging research in the brain is still largely preclinical. Animal models with Alzheimer’s-like pathology show NAD+ precursors can reduce amyloid burden and improve memory. Human data is sparse. A 2023 RCT in JAMA Network Open tested NR in adults with mild cognitive impairment over 48 weeks and found no significant difference in cognitive test scores compared with placebo — a sobering result for those hoping NAD+ supplements could slow dementia. However, researchers noted that the blood-brain barrier may limit how much peripheral NAD+ elevation reflects brain NAD+ changes.
NMN vs NR: Is There a Meaningful Difference?
This is one of the most common questions in the NAD+ space, and the honest answer is: not clearly, in humans.
| Feature | NMN (Nicotinamide Mononucleotide) | NR (Nicotinamide Riboside) |
|---|---|---|
| Molecular size | Larger; requires conversion to NR before cell entry (in most tissues) | Smaller; enters cells directly via specific transporters |
| Human RCT evidence | Growing; several trials 2020–2023 | Slightly more established; trials from 2018 onward |
| Typical doses studied | 250–900 mg/day | 250–2,000 mg/day |
| NAD+ elevation (blood) | Confirmed in multiple RCTs | Confirmed in multiple RCTs |
| Safety profile (short-term) | Appears well tolerated; limited long-term data | Well tolerated in trials up to 8 weeks; limited long-term data |
| Cost | Generally higher | Generally lower |
| Head-to-head human trial | None published as of mid-2024 | |
Both precursors appear to reach similar endpoints through slightly different biochemical routes. NMN is converted to NR before most cells can use it, and NR enters cells via nicotinamide riboside kinase pathways. Some researchers argue that NMN has a direct transport mechanism in the small intestine via the Slc12a8 transporter identified in mice — but whether this transporter is equally active in human gut tissue remains contested. Until a rigorous, adequately powered head-to-head trial is published, choosing between them on efficacy grounds is speculative. guide to longevity supplements
How to Apply This Practically
Given where the evidence currently stands, here is a rational approach to NAD+ supplementation for adults considering it:
- Establish your baseline first. NAD+ blood testing is available through several specialty labs. While not yet a standardized clinical test, having a baseline gives you a reference point to assess whether a supplement is actually working for you. This matters because individual responses vary considerably.
- Choose a well-characterized product. Look for NR or NMN supplements that have published third-party certificates of analysis (COA) from independent labs such as NSF International or USP. Supplement purity varies widely across brands, and some products tested by independent organizations have contained less than the labeled dose.
- Start at the lower end of studied doses. Most human RCTs showing blood NAD+ elevation used NR at 250–1,000 mg/day or NMN at 250–500 mg/day. Starting at 250–300 mg/day and titrating up makes sense given the absence of long-term safety data at higher doses.
- Take it in the morning. NAD+ plays a role in circadian rhythm regulation through SIRT1. Several researchers recommend morning dosing to align with the body’s natural NAD+ cycling, though this is based on mechanistic reasoning rather than direct timing trial data.
- Retest after 8–12 weeks. If you have baseline NAD+ levels, retesting after a consistent supplementation period tells you whether your levels have actually risen. Non-responders do exist.
- Do not treat it as a substitute for lifestyle foundations. Exercise, particularly resistance and aerobic training, independently raises NAD+ via AMPK and NAMPT pathways. Caloric restriction and fasting also elevate NAD+. The additive benefit of supplementation on top of an already active lifestyle may be smaller than the benefit in sedentary individuals. exercise and longevity pathways
Common Mistakes People Make
- Treating blood NAD+ as a definitive outcome. A supplement raising your blood NAD+ does not confirm it is doing the same in your brain, heart, or muscles. Blood is the most accessible tissue to measure, not necessarily the most relevant one for your health goals.
- Ignoring co-factors. NAD+ metabolism does not operate in isolation. Vitamin B3 (niacin), B2 (riboflavin), and B6 are all required at various steps of the NAD+ biosynthesis pathway. A diet chronically low in these nutrients may blunt the response to NR or NMN supplementation.
- Assuming more is better. High-dose niacin (a related NAD+ precursor) has well-documented risks at gram-level doses, including liver toxicity and flushing. NR and NMN appear better tolerated in short-term trials, but no long-term safety studies exist for doses above 1,000 mg/day. Exceeding studied ranges is not justified by current evidence.
- Overlooking potential interactions with cancer biology. NAD+ is required for DNA repair in healthy cells — but it is also required for rapidly dividing cancer cells. Some oncologists have raised theoretical concerns about high-dose NAD+ precursors in people with active cancer or high cancer risk. This does not mean they are harmful in this context, but it does mean consulting an oncologist before supplementing is reasonable.
- Expecting results in days. Even in trials showing significant NAD+ elevation, metabolic and functional changes — if they occur — emerge over weeks to months. Discontinuing after two weeks because you “don’t feel different” is not a meaningful self-experiment.
- Buying on price alone. The NAD+ supplement market includes products with poorly documented manufacturing processes. Paying a premium for third-party tested products is a reasonable risk-management strategy given current regulatory gaps.
Expert Recommendations
Leading researchers in the NAD+ aging field hold measured but genuinely interested positions on supplementation. David Sinclair, Professor of Genetics at Harvard Medical School and a prominent figure in the sirtuin-NAD+ field, has publicly stated he personally takes NMN daily — though he consistently acknowledges that human trial data remains insufficient to make broad population recommendations. His research group’s work in mice showing lifespan extension with NAD+ precursors is compelling, but he is careful to note the translation gap.
Charles Brenner, the biochemist who discovered NR as a NAD+ precursor and holds patents related to its use, has expressed skepticism about some of the more expansive longevity claims, arguing that the field should focus on well-designed clinical trials before promoting widespread use. His position reflects a legitimate tension in the field between the urgency of aging research and the need for rigorous human evidence.
The National Institute on Aging (NIA) is currently funding several trials examining NAD+ precursors in older adults across multiple sites in the US — a signal that the scientific establishment considers the question serious enough to invest public research dollars, while also recognizing that answers are not yet in hand.
For clinical practice, most metabolic and endocrinology specialists who engage with this literature suggest NAD+ supplements are reasonable for adults over 50 who are already practicing evidence-based lifestyle habits, have no contraindications, and have realistic expectations. They are not recommended as a first-line intervention or as a substitute for managing established cardiovascular, metabolic, or cognitive risk factors through proven means.
Frequently Asked Questions
Are NAD+ supplements safe?
Short-term safety data (up to 8–12 weeks) for NR and NMN at doses up to 1,000 mg/day looks reassuring based on current published trials, with side effects generally mild and transient (nausea, flushing at higher doses). However, there are no long-term human safety trials. People with cancer, liver disease, or taking medications metabolized by the liver should consult a physician before starting. This is not a supplement with a decades-long human safety record like vitamin D or magnesium.
How long does it take for NAD+ supplements to work?
Blood NAD+ levels typically rise within one to two weeks of consistent supplementation in trials. Functional changes, if they occur, appear to require longer — most positive findings in human trials emerge after six to twelve weeks of continuous use. It is also worth noting that some individuals show minimal blood NAD+ response, which is another argument for testing if you plan to supplement long-term.
Can you get NAD+ precursors from food instead?
Yes, to a degree. Niacin (vitamin B3), tryptophan, and nicotinamide are present in protein-rich foods including turkey, chicken, tuna, mushrooms, and peanuts. These dietary forms feed into NAD+ biosynthesis. However, the doses used in supplement trials substantially exceed what you could realistically obtain from food alone. A diet rich in these nutrients supports NAD+ metabolism but is unlikely to replicate the blood NAD+ elevations seen with supplementation.
Is there anyone who should not take NAD+ supplements?
People with active cancer should discuss with their oncologist, given NAD+’s role in supporting rapidly dividing cells. Those with liver disease should exercise caution, as NAD+ metabolism is heavily liver-dependent. Pregnant or breastfeeding individuals should avoid supplementation, as no safety data exists in these groups. Anyone taking medications — particularly those affecting sirtuin activity, PARP inhibitors used in oncology, or blood thinners — should consult a physician due to potential interactions.
The Bottom Line
NAD+ supplements, particularly NR and NMN, reliably raise blood NAD+ levels in humans — that much is well established. Whether that biochemical change translates into meaningful improvements in aging-related outcomes such as muscle function, metabolic health, or cognitive performance is still being worked out in ongoing clinical trials, and the current human evidence is promising but not yet definitive.
If you are a healthy adult over 40 who exercises regularly, eats well, manages stress, and sleeps adequately, adding an evidence-backed NAD+ precursor at a studied dose is a reasonable, low-risk addition to your health strategy — not a shortcut around the fundamentals. If you are hoping these supplements will do the work that lifestyle habits haven’t, the research does not support that expectation.
and does not constitute medical advice, diagnosis, or treatment. Always consult a
qualified healthcare provider before making changes to your diet, exercise routine,
supplement regimen, or any other health-related decisions.
References
- Martens CR et al. 2018. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. DOI: 10.1038/s41467-018-03421-7
- Yoshino M et al. 2021. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. DOI: 10.1126/science.abe9985
- Dolopikou CF et al. 2020. Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals. European Journal of Nutrition. DOI: 10.1007/s00394-019-01919-4
- Bertoldo MJ et al. 2020. NAD+ repletion rescues female fertility during reproductive aging. Cell Reports. DOI: 10.1016/j.celrep.2020.107987
- Elhassan YS et al. 2019. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports. DOI: 10.1016/j.celrep.2019.07.043
- Reiten OK et al. 2021. Preclinical and clinical evidence of NAD+ precursors supplementation improving mitochondrial dysfunction. Mechanisms of Ageing and Development. DOI: 10.1016/j.mad.2021.111506
- Aman Y et al. 2018. Therapeutic targets of NAD+ deficiency in aging. Cell Metabolism. DOI: 10.1016/j.cmet.2018.07.012
- Nikiforov A et al. 2015. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD accumulation. Journal of Biological Chemistry. DOI: 10.1074/jbc.M115.647kind
- Airhart SE et al. 2017. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLOS ONE. DOI: 10.1371/journal.pone.0186459
- Grozio A et al. 2019. Slc12a8 is a nicotinamide mononucleotide transporter. Nature Metabolism. DOI: 10.1038/s42255-018-0009-4